Webcasts of the EGAM 2015 plenary session are available for viewing

The plenary session presented information on the evolving structure of the EORTC as well as the clinical research landscape and new forms of clinical research activities covering the full span from early clinical trials to survivorship. Exchanging views with other stakeholders and discussing the role of academia will be major highlights.

EGAM 2015 also marked a special celebration in honor of Françoise Meunier, Director General and her many significant contributions to the EORTC over the past two and a half decades.


General introduction, Roger Stupp

The patients perspectives and survival issues, Isabelle Lebrocquy

Cancer Management and Transatlantic cooperation, Richard Schilsky

The EORTC Charitable Trust, Diego du Monceau

EORTC future perspectives, Roger Stupp

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023